Lethality in an anti-angiogenic tumor gene therapy model upon constitutive but not inducible expression of the soluble vascular endothelial growth factor receptor 1

Journal of Gene Medicine

Volumn 10, Issue 10, 2008, Pages 1083-1091

  Sivanandam, Vijayshankar Ganesh ^a   Stephen, Sam Laurel ^a   Hernandez Alcoceba, Ruben ^c   Alzuguren, Pilar ^c   Zabala, Maider ^c   van Rooijen, Nico ^d   Qian, Cheng ^c   Berger, Irina ^e   Gross, Marie Luise ^e   Prieto, Jesus ^c   Kochanek, Stefan ^a,b  

^a UNIVERSITY OF COLOGNE   (Germany)

^b UNIVERSITY OF ULM   (Germany)

^c UNIVERSITY OF NAVARRA   (Spain)

^d VU UNIVERSITY AMSTERDAM   (Netherlands)

^e UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Adenovirus vector; Sflt1; Toxicity; Tumor; VEGF

Indexed keywords

ADENOVIRUS VECTOR; ALANINE AMINOTRANSFERASE; ALBUMIN; ASPARTATE AMINOTRANSFERASE; CREATININE; MIFEPRISTONE; UREA; VASCULOTROPIN; VASCULOTROPIN INHIBITOR; VASCULOTROPIN RECEPTOR 1; ANGIOGENESIS INHIBITOR;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC GENE THERAPY; ARTICLE; ASCITES; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; C57BL 6 MOUSE; CANCER GENE THERAPY; CANCER INHIBITION; CAUSE OF DEATH; CELL STRAIN; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG FATALITY; ELECTRON MICROSCOPY; GENE EXPRESSION; GLOMERULUS BASEMENT MEMBRANE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; KIDNEY FAILURE; KIDNEY INJURY; MOUSE; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; UREA BLOOD LEVEL; VIRAL GENE DELIVERY SYSTEM; ADENOVIRUS; ANIMAL; C57BL MOUSE; CELL DIFFERENTIATION; CELL PROLIFERATION; EXPERIMENTAL NEOPLASM; GENE THERAPY; GENE VECTOR; GENETIC TRANSFECTION; GENETICS; HELA CELL; LIVER; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); TUMOR CELL CULTURE; TUMOR CELL LINE;

ADENOVIRIDAE; ANIMALIA;

ADENOVIRIDAE; ANGIOGENESIS INHIBITORS; ANIMALS; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL PROLIFERATION; GENE EXPRESSION; GENE THERAPY; GENETIC VECTORS; HELA CELLS; HUMANS; LIVER; MICE; MICE, INBRED C57BL; NEOPLASMS, EXPERIMENTAL; NEOVASCULARIZATION, PATHOLOGIC; TRANSFECTION; TUMOR CELLS, CULTURED; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 58149188896     PISSN: 1099498X     EISSN: 15212254     Source Type: Journal    
DOI: 10.1002/jgm.1244     Document Type: Article

References (33)

1. Folkman J. Angiogenesis and angiogenesis inhibition: an overview. EXS 1997; 79: 1-8.
2. Folkman J, Klagsbrun M. Angiogenic factors. Science 1987; 235: 442-447.
3. Shalaby F, Rossant J, Yamaguchi TP, et al. Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature 1995; 376: 62-66.
4. Fukumura D, Xavier R, Sugiura T, et al. Tumor induction of VEGF promoter activity in stromal cells. Cell 1998; 94: 715-725.
5. Jain RK, Duda DG, Clark JW, Loeffler JS. Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol 2006; 3: 24-40.
6. Kochanek S, Schiedner G, Volpers C. High-capacity 'gutless' adenoviral vectors. Curr Opin Mol Ther 2001; 3: 454-463.
7. Burcin MM, Schiedner G, Kochanek S, Tsai SY, O'Malley BW. Adenovirus-mediated regulable target gene expression in vivo. Proc Natl Acad Sci USA 1999; 96: 355-360.
8. Wang L, Hernandez-Alcoceba R, Shankar V, et al. Prolonged and inducible transgene expression in the liver using gutless adenovirus: a potential therapy for liver cancer. Gastroenterology 2004; 126: 278-289.
9. Kreppel F, Biermann V, Kochanek S, Schiedner G. A DNA-based method to assay total and infectious particle contents and helper virus contamination in high-capacity adenoviral vector preparations. Hum Gene Ther 2002; 13: 1151-1156.
10. Schiedner G, Hertel S, Johnston M, et al. Selective depletion or blockade of Kupffer cells leads to enhanced and prolonged hepatic transgene expression using high-capacity adenoviral vectors. Mol Ther 2003; 7: 35-43.
11. Schmitz V, Wang L, Barajas M, et al. Treatment of colorectal and hepatocellular carcinomas by adenoviral mediated gene transfer of endostatin and angiostatin-like molecule in mice. Gut 2004; 53: 561-567.
12. Collins I, Workman P. New approaches to molecular cancer therapeutics. Nat Chem Biol 2006; 2: 689-700.
13. Ton NC, Jayson GC. Resistance to anti-VEGF agents. Curr Pharm Des 2004; 10: 51-64.
14. Mitani K, Graham FL, Caskey CT, Kochanek S. Rescue, propagation, and partial purification of a helper virus-dependent adenovirus vector. Proc Natl Acad Sci USA 1995; 92: 3854-3858.
15. Morsy MA, Gu M, Motzel S, et al. An adenoviral vector deleted for all viral coding sequences results in enhanced safety and extended expression of a leptin transgene. Proc Natl Acad Sci USA 1998; 95: 7866-7871.
16. Kuo CJ, Farnebo F, Yu EY, et al. Comparative evaluation of the antitumor activity of antiangiogenic proteins delivered by gene transfer. Proc Natl Acad Sci USA 2001; 98: 4605-4610.
17. Klagsbrun M. Regulators of angiogenesis: stimulators, inhibitors, and extracellular matrix. J Cell Biochem 1991; 47: 199-200.
18. Carmeliet P. Angiogenesis in health and disease. Nat Med 2003; 9: 653-660.
19. Relf M, LeJeune S, Scott PA, et al. Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res 1997; 57: 963-969.
20. LeCouter J, Moritz DR, Li B, et al. Angiogenesis-independent endothelial protection of liver: role of VEGFR-1. Science 2003; 299: 890-893.
21. Mahasreshti PJ, Kataram M, Wang MH, et al. Intravenous delivery of adenovirus-mediated soluble FLT-1 results in liver toxicity. Clin Cancer Res 2003; 9: 2701-2710.
22. Sugimoto H, Hamano Y, Charytan D, et al. Neutralization of circulating vascular endothelial growth factor (VEGF) by anti-VEGF antibodies and soluble VEGF receptor 1 (sFlt-1) induces proteinuria. J Biol Chem 2003; 278: 12605-12608.
23. Foster RR, Hole R, Anderson K, et al. Functional evidence that vascular endothelial growth factor may act as an autocrine factor on human podocytes. Am J Physiol Renal Physiol 2003; 284: F1263-1273.
24. Eremina V, Sood M, Haigh J, et al. Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J Clin Invest 2003; 111: 707-716.
25. Pavenstadt H, Kriz W, Kretzler M. Cell biology of the glomerular podocyte. Physiol Rev 2003; 83: 253-307.
26. Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003; 349: 427-434.
27. Roes EM, Steegers EA, Thomas CM, et al. High levels of urinary vascular endothelial growth factor in women with severe preeclampsia. Int J Biol Markers 2004; 19: 72-75.
28. Maynard SE, Min JY, Merchan J, et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003; 111: 649-658.
29. Luttun A, Carmeliet P. Soluble VEGF receptor Flt1: the elusive preeclampsia factor discovered? J Clin Invest 2003; 111: 600-602.
30. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57-70.
31. Eskens FA, Verweij J. The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; a review. Eur J Cancer 2006; 42: 3127-3139.
32. Zhu X, Wu S, DahutWL, Parikh CR. Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. Am J Kidney Dis 2007; 49: 186-193.
33. George BA, Zhou XJ, Toto R. Nephrotic syndrome after bevacizumab: case report and literature review. Am J Kidney Dis 2007; 49: E23-E29.